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Abstract
Schistosomiasis is a debilitating neglected tropical disease, caused by flatworms of Schistosoma 
genus. The treatment relies on a single drug, praziquantel (PZQ), making the discovery of new 
compounds extremely urgent. In this work, we integrated QSAR-based virtual screening (VS) of 
Schistosoma mansoni thioredoxin glutathione reductase (SmTGR) inhibitors and high content 
screening (HCS) aiming to discover new antischistosomal agents. Initially, binary QSAR models 
for inhibition of SmTGR were developed and validated using the Organization for Economic Co-
operation and Development (OECD) guidance. Using these models, we prioritized 29 compounds 
for further testing in two HCS platforms based on image analysis of assay plates. Among them, 2-
*Corresponding Authors: For C.H.A.: phone, + 55 62 3209-6451; fax, +55 62 3209-6037; carolina@ufg.br. For F.P.S.-J.: phone, + 55 
21 3865 8248; fax, +55 21 2590 3495; floriano@ioc.fiocruz.br. 
Author Contributions
B.J.N., R.F.D., and M.R.S. contributed equally.
Notes
The authors declare no competing financial interest.
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmed-chem.5b02038.
More computational details regarding molecular finger-prints calculation and QSAR model development, as well as additional tables 
and figures of experimental results (PDF)
Molecular formula strings (CSV)
HHS Public Access
Author manuscript
J Med Chem. Author manuscript; available in PMC 2018 March 09.
Published in final edited form as:
J Med Chem. 2016 August 11; 59(15): 7075–7088. doi:10.1021/acs.jmedchem.5b02038.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[2-(3-methyl-4-nitro-5-isoxazolyl)vinyl]pyridine and 2-(benzylsulfonyl)-1,3-benzothiazole, two 
compounds representing new chemical scaffolds have activity against schistosomula and adult 
worms at low micromolar concentrations and therefore represent promising antischistosomal hits 
for further hit-to-lead optimization.
Graphical Abstract
INTRODUCTION
Schistosomiasis is a neglected tropical disease caused by flatworms of the genus 
Schistosoma. These worms cause a chronic and often debilitating infection that impairs 
development and productivity, and exposure to these worms is strongly linked to extreme 
poverty.1–4 Recent estimates of World Health Organization suggest that around 258 million 
people are infected resulting up to 200000 deaths annually. Currently, schistosomiasis is 
endemic in 78 countries worldwide, mainly in sub-Saharan Africa, the Middle East, the 
Caribbean, and South America, where infections are mediated through poor knowledge 
about the disease, poor sanitation, and lack of effective health policies.5
In the absence of a vaccine, the control of schistosomiasis relies on a single drug, 
praziquantel (PZQ), which has been used in clinical practice for almost four decades.6 
However, because of high incidence of reinfection, the widespread and repeated use of this 
drug in endemic areas raises concerns about the development of drug resistance by the 
parasite.7–11 This problem is further emphasized by the known lack of efficacy of PZQ 
against juvenile worms,12 which is a potential cause of treatment failure in endemic areas. 
Hence, there is an urgent need for new antischistosomal drugs with novel mechanisms of 
action.
The complete genome sequencing of Schistosoma mansoni,13,14 Schistosoma japonicum,15 
and Schistosoma hematobium16 has provided new information on their biological pathways, 
identifying potentially relevant targets for therapeutic intervention.17 Thioredoxin 
glutathione reductase (TGR) is one of these targets; it plays a crucial role in the redox 
homeostasis of the parasite.18 TGR is a multifunctional enzyme that acts in the 
detoxification of reactive oxygen species (ROS) generated by digestion of red blood 
cells19,20 and by the host immune system.21,22 In mammalian cells, there are two major 
systems to detoxify ROS, one is based on glutathione (GSH) and the other is based on 
thioredoxin (Trx). In both systems, NADPH provides reducing equivalents via two 
specialized oxidoreductase flavoenzymes. Glutathione reductase (GR) reduces glutathione 
disulfide (GSSG) and drives the GSH-dependent systems, whereas Trx reductases (TR) are 
pivotal in the Trx-dependent system. On the other hand, in schistosomes, thiol redox 
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homeostasis is completely dependent on TGR, which controls the NADPH reduction of 
GSSG and Trx in both systems.23–25 Given these characteristics, it is expected that the 
maintenance of the homeostatic levels of Trx and GSH in schistosomes play a key role in a 
variety of cellular processes such as defense against oxidative stress, DNA synthesis, 
detoxification, protein folding, and repair.26 Moreover, RNA interference studies have 
showed that inactivation of TGR of S. mansoni (SmTGR)18 and TGR of S. japonicum 
(SjTGR)27,28 has profound effects on worm survival rates both in culture medium and 
infected mice.
Due to the importance of TGR in parasite’s redox balance, we hypothesized that known 
SmTGR inhibitors listed on publicly available databases may serve as the chemical basis to 
discover new antischistosomal compounds by virtual screening (VS). Docking-based and 
pharmacophore-based approaches are the most popular VS strategies to identify putative hits 
in chemical libraries. However, in recent years, quantitative structure–activity relationships 
(QSAR) models have been used widely in VS applications as well.29–35
The main goal of this study was the identification of new structurally dissimilar compounds 
with high antischistosomal activity. To achieve this goal, we designed a study with the 
following steps: (i) collection, rigorously curation, and integration of the largest possible 
data set of SmTGR inhibitors, (ii) development of rigorously validated and mechanistically 
interpretable binary QSAR models, (iii) application of generated models for VS of three 
subsets from ChemBridge library (~150000 compounds), (iv) interpretation of developed 
models to derive structural rules useful for targeted design of new inhibitors, and (v) 
experimental validation of prioritized/designed hits on live schistosomula and adult worms 
in two distinct HCS platforms. As a result of this study, we found that the QSAR models 
were efficient for prediction of new SmTGR inhibitors and identified six novel 
antischistosomal hit compounds active against schistosomula and three hits active against 
adult worms. Among them, two hits, 2-[2-(3-methyl-4-nitro-5-isoxazolyl)vinyl]pyridine (3) 
and 2-(benzylsulfonyl)-1,3-benzothiazole (4), representing new chemical scaffolds 
structurally dissimilar to known inhibitors of S. mansoni, could be considered as promising 
antischistosomal agents.
RESULTS AND DISCUSSION
Data Set Balancing
Initially, thousands compounds with SmTGR inhibition data were retrieved from the 
PubChem Bioassay Database (AID: 485364) and used to build binary QSAR models. 
Further, uncurated chemical structures were standardized, duplicates were removed, and 
2854 compounds with reproducible potency (IC50) ≤10 μM were considered as inhibitors, 
whereas the remaining 337327 compounds were considered as noninhibitors. Because the 
original data set was highly unbalanced, i.e., 2854 inhibitors and 337327 non-inhibitors 
(1:118 ratio), it is not recommended for building binary QSAR models for the entire data 
set. During model building, most machine learning methods need equal weighting of the 
classes in terms of both the number of instances and the level of importance (i.e., active class 
has the same importance as inactive class). Consequently, when trying to predict a minority 
class in an unbalanced data set, machine learning methods are prone to assign most samples 
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to the majority class, resulting in a large number of erroneous predictions for minority class.
36
To reduce the number of the noninhibitors and ideally maintain the “chemical space” of the 
original data set, we evaluated the optimal number of representative compounds. To 
accomplish this task, we developed an undersampling workflow based on k-nearest 
neighbors (kNN) distances of the each noninhibitor to all inhibitors using the public 
available 166 substructures MACCS keys. We tested different sizes of the data set by 
removing noninhibitors and changing the inhibitors-to-noninhibitors ratios of 1:1 (balanced), 
1:2, and 1:3.
To visualize the structural diversity of our data set before and after balancing, we performed 
a principal component analysis (PCA). PCA transforms the original measured variables into 
new orthogonal variables called principal components, which are a linear combination of the 
original variables. Detailed results of structural diversity investigation are shown in 
Supporting Information, Figure S1. The top two principal components retained 20% of the 
original information. Supporting Information, Figure S1A, represents the PCA plot of 2854 
inhibitors (blue dots) vs all 337327 noninhibitors (gray dots). As we can see, the inhibitors 
are widely distributed across chemical space, reflecting significant chemical diversity. 
Supporting Information, Figure S1B–D, shows the non-inhibitors selected with different 
ratios: 1:1 or 2854 non-inhibitors, Figure S1B; 1:2 or 5705 noninhibitors, Figure S1C; and 
1:3 or 8562 noninhibitors, Figure S1D. As we can see from the distribution of these dots, the 
most representative compounds were chosen that allowed minimal reduction of the original 
chemical space.
Performance of Individual QSAR Models
The balanced (ratio of 1:1) and unbalanced data sets (ratios of 1:2 and 1:3) were modeled by 
a combination of AtomPair,37,38 molecular access system (MACCS),39–41 and Morgan 
fingerprints,38,42 chemistry development kit (CDK),43 and Dragon descriptors44,45 along 
with eight machine learning methods leading to 120 different binary QSAR models 
(Supporting Information, Tables S1, S2, and S3). According to the statistical results of a 5-
fold external cross-validation procedure, we could draw three general conclusions: (i) 
random forest (RF), support vector machine (SVM), and gradient boosting machine (GBM) 
methods showed the best prediction ability among the eight tested machine learning 
methods; (ii) QSAR models built on balanced data sets are better than unbalanced (1:2 and 
1:3 ratios) due to discrepant values between sensitivity (SE) and specificity (SP), the latter 
are prone to assign most samples as noninhibitors, resulting in a large number of erroneous 
predictions; and (iii) the QSAR models which were built from the balanced data set showed 
a high level of agreement between correct classification rate (CCR), SP, and SE values. 
Table 1 shows the detailed performances of the more predictive QSAR models derived from 
the balanced data set.
The combination of Morgan fingerprints with RF (Morgan–RF), MACCS key with RF 
(MACCS–RF), AtomPair finger-prints with SVM (AtomPair–SVM) and GBM (AtomPair–
GBM), Dragon descriptors with SVM (Dragon–SVM) and GBM (Dragon–GBM), and CDK 
descriptors with SVM (CDK–SVM) led to more predictive QSAR models, with correct 
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classification rate (CCR) ranging between 0.81 and 0.85 and coverage of 0.62–0.77 (Table 
1). The best individual model was built using the combination of Morgan–RF (CCR = 0.85, 
SE = 0.85, and SP = 0.86).
To ensure that the accuracy of the models was not due to chance correlation, 10 rounds of Y-
randomization were performed for each data set (Supporting Information, Table S4). The 
results from this analysis (CCR values around 0.50) indicate that our models built using 
balanced data set are statistically robust.
Performance of Consensus Models
Several individual QSAR models were generated using multiple machine learning 
algorithms and descriptors/fingerprints. However, our previous experience suggests that 
consensus models that combine individual QSAR models are advantageous46–49 and 
naturally minimize prediction errors during a VS campaign. Therefore, consensus models 
were built by averaging the predicted values obtained after combining the individual models 
built using the balanced data set. The detailed performances of 12 consensus models are 
given in Supporting Information, Table S5. Among them, the consensus model built by 
combining the Morgan–RF, MACCS–RF, AtomPair–SVM, Dragon–SVM, and CDK–SVM 
(Table 1 and Supporting Information, Table S5) showed the best performance among all 
constructed consensus models (CCR = 0.87, SE = 0.87, and SP = 0.88). This consensus 
model discriminates inhibitors and noninhibitors better than any of the individual QSAR 
models, with a 2% of increase in CCR, SE, and SP when compared with the best individual 
model (Morgan–RF).
In addition, the most rigorous consensus model (consensus rigor)46 was built by combining 
five individual models with more restrictive conditions. A consensus rigor model only 
considers the outcome to be reliable when a compound was inside the applicability domain 
(AD) for the five models. If the compound was outside the AD for any model, then the 
outcome was specified as unreliable. Expectedly, the combination of Morgan–RF, MACCS–
RF, AtomPair–SVM, Dragon–SVM, and CDK–SVM models (Tables 1 and Supporting 
Information, Table S5) also showed the best performance among all built consensus rigor 
models (CCR = 0.91, SE = 0.96, and SP = 0.87). In summary, the best consensus rigor 
model demonstrated better statistical results, with a 5% of increase in CCR, and 11% of 
increase in SE when compared with the best individual model (Morgan–RF). Although the 
AD of consensus rigor is limited only for certain chemical classes (coverage of 0.38), it has 
very high predictive power (CCR = 0.91).
Model Interpretation
The Morgan–RF model exhibited the best predictive performance, and, consequently, it 
possesses the features that are best correlated with SmTGR inhibition activity. Therefore, we 
translated its features (fingerprints) into predicted probability maps (PPMs) and visualized 
the atomic and fragment contributions predicted by the QSAR model (Figures 1 and 2). 
Atoms and fragments promoting the inhibition are highlighted by green (Figure 1), atoms 
and fragments decreasing the inhibitory potential are highlighted by purple (Figure 2), and 
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gray lines (Figures 1 and 2) delimit the region of split between the favorable and the 
unfavorable contributions.50
Analyzing the fragments with favorable contributions highlighted by PPMs, we noticed that 
14 fragments were more frequent in the inhibitors set and absent in the noninhibitors set 
(Figure 1). Examples of favorable fragments for SmTGR inhibition activity are nitrofuran, 2-
ethenylfuran, (ethanesulfonyl) benzene, 2-(sulfonylmethyl) furan, carbonyl thiourea, and 4-
methanesulfonyl-1,3-oxazole. By analyzing the fragments with unfavorable contribution into 
SmTGR inhibition activity (Figure 2), several fragments, such as benzylsulfonamide, 
methylurea, morpholine-4-carbonyl, piperidine-4-carboxamide, 1-
methanesulfonylpiperidine, and cyclohexanecarbonyl, were more frequent in the 
noninhibitors set. Compounds that contain these fragments may show a decreased SmTGR 
inhibitory activity. This information could be useful for designing or optimizing new 
SmTGR inhibitors by replacing unfavorable fragments by favorable fragments.
Reaction Mechanism of SmTGR Inhibition
Although the inhibition mechanisms of most of the SmTGR inhibitors are not well 
understood at the molecular level, the reaction mechanisms by which oxadiazole-2-oxides 
and cephalosporins operate could be identified according to a graphical interpretation of 
PPMs. However, for the best understanding of molecular inhibition mechanisms, it is 
important to highlight that the active site of SmTGR is composed by a cysteine pair (Cys28/
Cys31) in the glutharedoxin domain, a cysteine pair (Cys154/Cys159) in the thioredoxin 
domain, and a redox-active cysteine/selenocysteine pair (Cys596/Sec597) in the C-terminal 
tail. The latter should be highly mobile to accept electrons from the Cys154/Cys159 pair and 
to donate electron pairs to Cys28/Cys31 pair.24 These amino acids provide the perfect 
chemical environment for covalent inhibition. The higher nucleophilicity and low pKa of the 
selenol group of Sec are thought to confer Sec a catalytic advantage over Cys at the 
attacking position.51–53 Nonetheless, the thioredoxin domain contains His571 and Glu576, a 
catalytic dyad that can facilitate proton abstraction of Cys159, thus impacting the catalytic 
efficiency of the thioredoxin domain of SmTGR.24
We observed that the carbons 3 and 4 of the oxadiazole-2-oxide core presented the most 
important contributions for SmTGR inhibition activity (Figure 3A–C). With PPMs 
information for this chemotype, a mechanistic rationale for inhibition was initiated through 
nucleophilic attack (presumably by a thiolate or selenoate of Cys or Sec, respectively) at 
either the position 3 or 4 of the oxadiazole ring and subsequent rearrangement of the 
heterocycle in a manner that allows release of the nitroxyl anion. An enzymatic oxidation is 
posited to transform this agent to nitric oxide (Figure 3D). These pieces of information 
corroborate with mechanism of inhibition proposed by Rai and colleagues54 and mechanism 
of nitric oxide release in physiological solution under the action of thiols studied by Gasco 
and colleagues55 In addition, PPMs indicated that the presence of amine-oxide group in core 
and electron-withdrawing substituents, such as carbonyl, at R1 and R2 positions are 
favorable for SmTGR inhibition (Figure 3A), while removal of the amine-oxide group 
(Figure 3B) and presence of electron deficient substituents at R1 and R2 positions (Figure 
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3C) leads to modest potencies in terms of SmTGR inhibition. These pieces of information 
corroborate with structure–activity relationships rules established by Rai and colleagues.54
The reaction mechanism by which cephalosporins exert their SmTGR inhibition activity was 
also proposed using the PPMs information (Supporting Information, Figure S2A). For both 
compounds, the PPMs picked up the positive contributions of the basic core structure of 
cephalosporines, more specifically carbon 8 and nitrogen 5 of β-lactam ring, and partially 
positive contribution of 1-methyl-5-tetrazolethione core for inhibition of SmTGR. On the 
basis of these results, we suggest that inhibition of SmTGR by cephalosporins may occur via 
a mechanism similar to proposed by Triboulet and colleagues,56 i.e., a nucleophilic attack of 
Cys or Sec on β-lactam carbonyl carbon, with formation of a tetrahedral intermediate, which 
collapses with β-lactam ring opening by N5–C8 bond fission. Then, the acyl-enzyme 
intermediate could hydrolyze or react further, with expulsion of the 1-methyl-5-
tetrazolethione from carbon 3 generating a reactive methylene that could be trapped by other 
thiolate or selenoate (Supporting Information, Figure S2B).
QSAR-Based Virtual Screening
The QSAR-based VS was carried out following the workflow presented in Figure 4. 
Initially, 150000 compounds available on PremiumSet, DIVERSet-CL, and DIVERSet-EXP 
libraries of ChemBridge were downloaded and prepared for VS. As drug-like ligands are 
highly desirable for the development of new leads with good oral bioavailability, we first 
filtered these libraries and excluded 1285 compounds that violated Veber57 and Lipinski’s 
rules.58 The remaining compounds were predicted by the consensus and consensus rigor 
models. To narrow down the compounds list and to obtain the highest level of confidence for 
each prediction, we took both the consensus score (average class prediction) and consensus 
model coverage into consideration. Consensus model coverage was defined as a fraction of 
individual models for which a compound was found to fall within the respective ADs. In that 
sense, introducing probability cutoffs can lead to predictions with higher confidence. 
Therefore, only putative hits with an average class number prediction of 1.0 and consensus 
model coverage over 50% were selected (470 putative hits). In addition, we removed 
compounds with previous bioactivity data reported against SmTGR or S. mansoni and pan-
assay interference compounds (PAINs)59,60 so that selected compounds would be novel 
SmTGR inhibitors and contain no PAINs structures. Finally, the compounds were evaluated 
by predicting a panel of properties including high aqueous solubility (CIQPlogS),61 
acceptable binding to human serum albumin (QPlogKhsa),61 acceptable brain/blood 
partition coefficient (QPlogBB),61 nonblocking or weak blocking of hERG channel,46,47 and 
absence of carcinogenicity and hepatotoxicity.32 At the end of the VS workflow, 29 putative 
hits were visually inspected and acquired for biological evaluation (Supporting Information, 
Table S6).
Ex Vivo Activity Against Schistosomula
Compared to target-based VS approaches, the traditional whole-organism schistosome 
screening approach (phenotypic screening) is an old but indispensable method to discover 
new antischistosomal agents. This phenotypic approach may be used to validate if the 
predicted SmTGR-inhibitor interaction has antischistosomal activity. Moreover, a validated 
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compound from a phenotypic assay must have been able to reach its target within the 
assayed organism only after crossing several biological membranes and resisting degradation 
by detoxification enzymes. Hence, a hit coming from a phenotypic screen has much more 
biological value than one coming from a simple biochemical assay. Advances in automated 
microscopes, liquid handling systems, and computer-based image analysis programs have 
enabled the development of high-throughput phenotypic assays with cells or small whole 
organisms, a technique known as high-content screening (HCS).62,63 HCS microscopes are 
able to capture high resolution images of live organisms in quick succession, a feature that 
has been explored to evaluate phenotypic and motility changes in schistosomula64 or adult 
worms.65,66
Therefore, we employed a HCS assay to evaluate the biological activity of the selected 
compounds from virtual screening against the S. mansoni schistosomula. Assaying against 
this larval stage is commonly used as an initial screening step in antischistosomal drug 
discovery campaigns67–72 because schistosomula are easier to obtain in larger numbers than 
adult worms. Of the 29 compounds tested against schistosomula, six were declared 
confirmed actives based on motility and phenotype scores at 20 μM after 48 h of exposure 
(Supporting Information, Table S6). The chemical structures of the six primary hits are 
shown in Figure 5.
Following the initial screening on schistosomula, the six primary hits were selected for 
determining half-maximal motility concentration (EC50) at 0.31–20 μM range (Table 2 and 
Supporting Information, Figure S3). Among primary hits, 1,2-dimethoxy-4-(2-
nitrovinyl)benzene (1), 1-(4-iodophenyl)-3-(4H-1,2,4-triazol-3-ylthio)-2,5-pyrrolidinedione 
(2), 3-[(4-acetylphenyl)amino]-1-(2-thienyl)-1-propanone (5), and 3-(2-furyl)-1-phenyl-1H-
pyrazole-4-carbonitrile (6) only showed inhibition activity at the highest tested concentration 
(>20 μM). On the other hand, 2-[2-(3-methyl-4-nitro-5-isoxazolyl)-vinyl]pyridine (3) and 2-
(benzylsulfonyl)-1,3-benzothiazole (4) showed efficacy in the same range of activity of the 
reference drug PZQ (EC50 = 1.90 μM), with EC50 values of 3.23 and 2.62 μM, respectively. 
This is an important feature for a new antischistosomal drug because modern lead discovery 
pipelines prioritize compounds that possess bioactivity across the entire developmental cycle 
of the parasite in the mammalian host.73,74
Analysis of Phenotypic Profile
Compounds 3 and 4 promoted the internal disruption of larvae as evidenced by the 
appearance of multiple vacuoles as well as the rounding and darkening of the schistosomula 
(Figure 6). To evaluate if schistosomula response profiles toward hits resemble those 
observed in the presence of known antischistosomal drugs (OLT, PZQ, dihydro-artemisinin, 
methylclonazepam, Ro15-5458, and oxamniquine), we applied a Bayesian treatment class 
model using phenotype scores.64 This analysis indicated a shared target and/or mechanism 
of action between OLT and hits, and therefore, all six hits were classified as OLT-like 
compounds. At least in part, these results could be related to SmTGR inhibition because 
OLT has already been identified as a noncompetitive inhibitor of this enzyme. It is also 
important to note that these phenotypic profile has been also observed after SmTGR gene 
knockout.18
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Ex Vivo Activity on Adult Worms
Our next step was to investigate if the compounds identified as hits for schistosomula also 
had an effect on adult S. mansoni worms.65,66 Therefore, we employed a new HCS platform 
recently developed by our group that allows for systematic evaluation of gender-, dose-, and 
time-dependent drug effects on individual male and female parasites by measuring over 100 
image features related to worm motility and morphology. Previously, we have demonstrated 
the successful application of this platform in identification of potent antischistosomal hit 
compounds.65,66 In this study, four compounds (1–4) were screened at 0.1–100 μM 
concentrations for incubation times varying from 0 h (immediately after compound addition 
to culture medium) to 72 h.
Inspection of the measured features suggested that at least three features were able to 
distinguish active from inactive compound concentrations or the DMSO control: the 
Overlap_RandIndex feature, which is related to motility, the intensity, and the area of the 
identified worm object. Figure 7 shows a 3D plot of these relevant features for individual 
female worms exposed to the investigated compounds at 20 μM concentration as well as for 
the PZQ and negative control (treated with 0.1% DMSO) after 48 h incubation. The sample 
images are shown to exemplify the phenotypes that can be captured by these features. In 
general, the feature most correlated to the antischistosomal activity of these compounds was 
the Overlap_RandIndex, which roughly measures the difference in worm position from one 
time-lapse frame to the next and is inversely proportional to worm motility in a scale varying 
from 0 to 1. For simplicity, we hereafter refer to this feature as the “motility score”.
To determine the potency of the hit compounds against adult worms with the reference drug 
PZQ, we have determined EC50 values from dose response curves against male and female 
worms with varying incubation times (Supporting Information, Table S7 and Figure S7). 
Compounds showed motility inhibition potencies against adult worms ranging from 4.91 to 
35 μM, depending on incubation time and gender (Table 2). Overall, inhibition was fully 
achieved after 48 h of incubation (Table 2). Compound 3 was the most active, with EC50 
around 6.00 μM for both genders. Compounds 1 and 4 showed satisfactory potencies (<10 
μM) for female worms, with EC50 = 5.77 and 4.91 μM, respectively, but not for male worms. 
Compound 2 was the less potent, with EC50 values of 10.2 and 17.9 for male and female, 
respectively. Despite the satisfactory potencies displayed, all compounds had a less 
pronounced effect on adult worms than PZQ at all incubation times (EC50 values ≤0.66 μM, 
see Supporting Information, Table S2). Results also indicated that female worms and 
schistosomula are slightly more sensitive to compounds action because they showed EC50 
values up to 5–8 times lower than those determined in males. In part, this could be due to a 
gender-specific expression pattern of SmTGR and immature antioxidant system of the 
schistosomula. In fact, schistosomula express lower levels of SmTGR than adults, which 
make them more susceptible to oxidative damage caused by inhibitors.75,76
Cytotoxicity Against Human Cells
Compounds 1–4 and PZQ were further evaluated for its cytotoxicity against human 
epithelial cells (WSS-1) from human kidney using a resazurin-based viability assay (Table 
2). PZQ showed the lowest cytotoxicity, exhibiting half-maximal cytotoxic concentration 
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(CC50) above 400 μM. Compounds 2, 3, and 4 only were cytotoxic in concentrations higher 
than those necessary for antischistosomal activity. Compound 2 was the least cytotoxic 
compound (CC50 = 133.40 μM), followed by 4 (CC50 = 28.49 μM), 1 (CC50 = 17.48 μM), 
and 3 (CC50 = 16.38 μM).
Controls for Nonspecific Inhibition and Off-Target Effects
Colloidal aggregates have long plagued early drug discovery. When a colloid is formed, 
membrane and soluble proteins adsorb to its surface and are partially denatured, leading to 
nonspecific inhibition and occasionally activation.77,78 Therefore, adult worms were 
coincubated with investigated compounds (at 20 and 100 μM) and detergent Triton X-100 
(0.01%) and their antischistosomal effect was compared with activities obtained without 
detergent for excluding a possible promiscuous colloidal aggregate effect. No significant 
differences were observed after comparison of inhibition activities of both groups, showing 
that antischistosomal activity of the hit compounds is related to specific inhibition 
(Supporting Information, Figure S5). Further, we also investigated possible off-target effects 
of the hit compounds toward nucleophilic thiols in a papain inhibition assay. Again, none of 
the antischistosomal hits showed significant inhibition of papain at 100 μM while positive 
control E-64 fully inhibits this enzyme at 20 μM concentration (Table 2 and Supporting 
Information, Figure S6).
CONCLUSIONS
To the best of our knowledge, this is the first study integrating QSAR-based VS and HCS 
methods to discover new antischistosomal agents. We have developed robust and predictive 
QSAR models for antischistosomal activity. Developed models were used in the most 
conservative way, i.e., in consensus fashion with the strictest AD criteria, for VS of three 
ChemBrigde data sets: DIVERSet-CL, DIVERSet-EXP, and PremiumSet. As a result, 470 
putative SmTGR inhibitors were identified. Then, 29 compounds were selected and tested 
against S. mansoni schistosomula using a HCS platform and six of them showed significant 
inhibition activities at 20 μM. Among them, compounds 3 and 4 showed inhibitory effect 
equivalent to PZQ, with EC50 values around 2.50 μM. Both hits were also classified as OLT-
like compounds, indicating a shared target with OLT, which has already been identified as an 
inhibitor of SmTGR.79 The results of gender-, dose-, and time-dependent inhibitory effect 
indicated that adult female worms of S. mansoni are slightly more sensitive than males to 
compounds action. Compounds 3 and 4 showed satisfactory potencies for female worms, 
with EC50 values around 6.00 μM. Both compounds also demonstrated low cytotoxicity to 
WSS-1 mammalian cells (CC50 > 16 μM) and inhibition of papain only in concentrations 
>100 μM. Finally, both compounds represent new chemical scaffolds which are structurally 
dissimilar to known inhibitors of S. mansoni and thus can be considered as new hit 
compounds for further chemical optimization.
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EXPERIMENTAL SECTION
Computational
Data Set—The QSAR models were developed according to best practices of predictive 
QSAR modeling,80,81 which is fully compliant to Organization for Economic Co-operation 
and Development (OECD) guidance on development and validation of QSAR models such 
as (i) a defined end point, (ii) an unambiguous algorithm, (iii) a defined domain of 
applicability, (iv) appropriate measures of goodness-of-fit, robustness, and predictivity, and 
(v) mechanistic interpretation.82 All in silico steps developed in this study were 
implemented in a publicly available KSAR workflow (http://labmol.farmacia.ufg.br/ksar). 
The KSAR workflow is tightly integrated with R and KNIME and includes many modules 
such as the module for preparing the data, PCA, building of QSAR models, and VS.46,83 We 
first retrieved 359841 compounds containing half-maximal inhibitory concentration (IC50) 
data for the SmTGR enzyme from the PubChem BioAssay database (AID: 485364). 
Compounds with inconclusive IC50 results were considered experimental errors and thus 
were not included in this study to avoid noise in model building. A total of 2854 out of these 
359841 compounds had reproducible potency (IC50 ≤ 10 μM) and were considered as 
inhibitors, whereas the remaining 356987 compounds were considered as noninhibitors.
Data Set Curation—Each compound of data set was carefully standardized according to 
the protocol proposed by Fourches and colleagues.84,85 Briefly, explicit hydrogens were 
added and salts were removed, whereas specific chemotypes such as aromatic and nitro 
groups were normalized using ChemAxon Standardizer (v.6.1.2, ChemAxon, Budapest, 
Hungary, http://www.chemaxon.com). Polymers, inorganic salts, organometallic 
compounds, and mixtures were also removed. In addition, 4437 compounds with multiple 
SmTGR measurements were identified during analyses of duplicates. Further analysis 
showed high concordance (99.9%) of duplicated records. In addition, 345 compounds with 
molecular weight greater than 700 Da were removed. In the end, the prepared data set 
contained 2854 inhibitors and 337327 noninhibitors.
Molecular Fingerprints and Descriptors—Three different types of fingerprints were 
used in this study: the Morgan fingerprint, a RDKit implementation38 of the extended-
connectivity fingerprints,42 with radius of 2 and bit vector of 1024 bits; the MACCS 
structural key fingerprints;39–41 and the AtomPair fingerprints (RDKit implementation38 of 
the Carhart’s atom pairs)37 with bit vector of 1024 bits. All the fingerprints were calculated 
by the open-source cheminformatics toolkit RDKit v.2.4.0.86 A brief description of Morgan, 
AtomPair, and MACCS fingerprints is available in Supporting Information.
The Chemistry Development Kit (CDK, v.1.4.19, GNU Lesser General Public License) 
descriptors and 0–2D descriptors were calculated using the PaDEL-Descriptor program43 
and DRAGON (v.5.5, Talete SRL, Milan, Italy), respectively. The complete list of CDK 
descriptors and a detailed discussion for DRAGON descriptors can be found elsewhere.44,45 
The descriptors matrix was then normalized and constant/near constant and highly correlated 
(r ≥ 0.9) descriptors were removed.
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Data Set Analysis and Undersampling—Because the original library was highly 
unbalanced (2854 inhibitors and 337327 non-inhibitors), it is not recommended for building 
binary QSAR models for the entire data set. Thus, we decided to balance the data set. Unlike 
the traditional undersampling methods which randomly balance the data set, our linear 
undersampling strategy retains most of the representative structures of the noninhibitors set, 
thus ensuring as high as possible coverage of original chemical space. The basic principle 
here is to measure the whole inhibitors matrix represented by the MACCS key fingerprints 
evaluating the Euclidean distance to the MACCS key fingerprints of each noninhibitor using 
a kNN method,87 implemented in R software v.3.0.3.88 Then, the samples on noninhibitors 
set were linearly extracted over the whole set by using k-distances and were used to generate 
balanced and partially balanced data sets. Finally, we generated three undersampled data sets 
with inhibitor-to-noninhibitor ratios of 1:1 (2854 inhibitors and 2854 noninhibitors), 1:2 
(2854 inhibitors and 5705 noninhibitors), and 1:3 (2854 inhibitors and 8562 noninhibitors).
Machine Learning Implementation—The building and optimization of statistically 
acceptable QSAR models requires a close combination between chemical information (i.e., 
fingerprints or descriptors) and several machine learning classifiers. For this reason, eight 
different machine learning classifiers, including the SVM with the radial basis Kernel 
function,89 the RF,90 GBM,91 and partial least-squares discriminant analysis (PLS-DA)92 
approaches, classification and regression trees (CART),93 kNN with Euclidean distance,87 
multilayer perceptron (MLP),94 and multivariate adaptive regression splines (MARS)95 were 
used. All machine learning classifiers were implemented using the R v.3.0.3.88 A brief 
description about the theory of each machine learning method is described in Supporting 
Information.
5-Fold External Cross-Validation—The full data set of compounds with known 
inhibition activities is randomly divided into five subsets of equal size; then one of these 
subsets (20% of all compounds) is set aside as an external validation set and the remaining 
four sets together form the modeling set (80% of the full set). This procedure is repeated five 
times, allowing each of the five subsets to be used as external validation set. Models are built 
using the modeling set only, and it is important to emphasize that the compounds in 
momentary external set (fold) are not employed either to build or select the models.
Applicability Domain—The AD for each descriptor or fingerprint type was estimated 
based on the Euclidean distances among the training set of each QSAR model generated in 
the external 5-fold cross-validation procedure. The distance of a test compound to its nearest 
neighbor in the training set was compared to the predefined AD threshold level. If the 
distance was greater than this threshold level, the prediction was considered to be less 
trustworthy.96 In this study, we defined AD as a distance threshold DT between a compound 
under prediction and its closest nearest neighbors of the training set. It was calculated as 
follows:
(1)
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Here, ȳ is the average Euclidean distance of the k nearest neighbors of each compound 
within the training set, σ is the standard deviation of these Euclidean distances, and Z is an 
arbitrary parameter to control the significance level. We set the default value of this 
parameter Z at 0.5. Thus, if the distance of the external compound from all of its nearest 
neighbors in the training set exceeds this threshold, the prediction is considered unreliable.
Evaluation of Performance and Robustness—To access the predictive performance 
of the binary QSAR models, SE, SP, and CCR were used. These statistic metrics are 
calculated by the following equations:
(2)
(3)
(4)
Here, TP and TN represent the number of true positives (correct classifications of 
inhibitors), and true negatives (correct classifications of noninhibitors), respectively, while 
FP and FN represent the number of false positives (incorrect classifications of inhibitors) 
and false negatives (incorrect classifications of noninhibitors), respectively.
In addition to the above model evaluation metrics, Cohen’s κ (k) was used to measure the 
agreement between model predictions and experimental data.97 This statistical parameter is 
calculated by the following equations:
(5)
(6)
(7)
Here, N denotes the total number of compounds, Pr(a) represents the relative observed 
agreement between the predicted classification of the model and the known classification, 
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and Pr(e) is the hypothetical probability of chance agreement. In the end, k analysis returns 
values between −1.0 (no agreement) and 1.0 (complete agreement), but values between 0.6 
and 1.0 denote that the model is predictive. Finally, to further ensure that the robustness of 
the models was not due to chance correlation, 10 rounds of Y-randomization were performed 
for each constructed model.
Consensus Modeling—After the building of QSAR models using all pairwise 
combinations of different types of chemical descriptors/fingerprints and various machine 
learning methods, the best models were used for consensus modeling, which can be derived 
by calculating an average for individual models. In consensus modeling, the final predicted 
value for each compound is estimated by including an average of the predicted values from 
the set of QSAR models. Thus, the averaged predicted activity for each compound is in the 
[0, 1] range. Formally, compounds with the predicted activity higher than 0.5 are classified 
as inhibitors, and those with the predicted activity lower than 0.5 are classified as 
noninhibitors. Obviously, the closer the average predicted value is to 1 or 0, the higher the 
concordance among all models and the higher our confidence is in the classification of 
compounds as inhibitors or noninhibitors, respectively.
Mechanistic Interpretation—To explore favorable or unfavorable structural fragments 
for SmTGR inhibition, the PPMs were generated to visualize the atomic and fragment 
contributions predicted by the best QSAR model.50
Virtual Screening—The purpose of VS is to identify in a library of chemicals a subset of 
compounds with the desired properties based on computational calculations. Here the 
DIVERSet-CL, DIVERSet-EXP, and PremiumSet diversity data sets taken from the 
ChemBridge database were screened to identify inhibitors of SmTGR. Prior to screening, 
the data sets were curated in the same way as modeling set (see Data Set Curation section) 
and filtered using the Veber57 and Lipinski’s rules58 to obtain drug-like compounds. 
Fingerprints and molecular descriptors were generated for all compounds and normalized 
(except fingerprints) based on the minimum and maximum values of each descriptor of the 
modeling set. Then, best consensus and consensus rigor models were used to predict the 
SmTGR inhibition activity of compounds. The prediction results were accepted only when 
the compound was found within the applicability domains of more than 50% of all models 
used in consensus prediction. In addition, to estimate the structural novelty of putative hits, 
we calculated the pairwise Tanimoto coefficients (using MACCS key fingerprints) between 
each screened putative hit and compounds in the full data set of SmTGR inhibitors. Then, 
putative hits with previous bioactivity data against SmTGR or S. mansoni were identified 
and PAINS were removed using a workflow developed by Saubern and colleagues.98 Finally, 
hits were imported into Maestro workspace v.9.3 and their aqueous solubility (CIQPlogS), 
binding to human serum albumin (QPlogKhsa), and brain/blood partition coefficient 
(QPlogBB) properties were predicted using QikProp v.3.4,61 and hERG inhibition, 
carcinogenicity, and hepatotoxicity were predicted using the Pred-hERG server,46,47,99 
admetSAR server,100,101 and PaDEL-DDPredictor program,102,103 respectively.
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Experimental
Materials—Investigated compounds were purchased from ChemBridge (San Diego-CA, 
USA), resuspended in 100% DMSO, and used immediately in the assays. It is important to 
mention that all chemical structures were confirmed using proton (1H) NMR spectra at 
300/400 MHz and liquid chromatography–mass spectrometry (LC-MS) analysis with 
evaporative light scattering and ultraviolet detectors confirmed a minimum purity of 95% for 
all compounds (spectra of compounds are listed in Supporting Information). DMEM and 
M169 media were purchased from Vitrocell Embriolife (Campinas-SP, Brazil). All other 
reagents were purchased from Sigma-Aldrich (St. Louis-MO, USA).
Automated ex Vivo Larval S. mansoni HCS Assay—Cercarie (S. mansoni, BH 
strain) were vortexed at maximum speed for 5 min for tail shedding and transformation into 
schistosomula by an adapted method from literature.104,105 Briefly, schistosomula were 
resuspended in Medium 169, placed in 384-well plates (120 per well), and maintained in an 
incubator with 5% CO2 overnight before compound addition. The worms were then 
incubated with investigated compounds and PZQ at 0.31–20 μM concentrations or DMSO 
(0.625%). The effect of the compounds on schistosomula motility and phenotypes was 
assessed at 48 h after compound addition using an automated bright-field 
ImageXpressMicro HCS microscope (IXM; Molecular Devices, Wokingham, UK). For 
motility analysis 5 × 11 s interval time-lapse images were collected using a 4× objective. For 
detailed morphology, a 10× objective was used to collect four adjacent images fields from 
within a well in order to increase the number of schistosomula for phenotype analysis. 
Analysis of both the larval phenotype and motility was then carried out in Pipeline Pilot 9 as 
described by Paveley and colleagues.64 Phenotype analysis of individual parasites was 
carried out by a two class Laplacian-modified Bayesian categorization analysis of 80 image 
descriptors which constituted shape, size, image intensity, and texture statistics and 
compared to a training set of data comprising 20000 parasites. Motility analysis of 
individual parasites was also carried out by the average object displacement from the origin 
point in subsequent 4× image across the time frame series. Both the Bayesian phenotype and 
motility scores were subsequently adjusted to the control wells (DMSO treated) on each 
plate.64
Automated ex Vivo Adult S. mansoni HCS Assay—After 42–49 days post 
percutaneously infection of infant Swiss mice with 150 ± 10 S. mansoni cercariae (BH 
strain), animals were euthanized, and worms perfused from portal hepatic and mesenteric 
veins. Male and female parasites were rinsed and individually transferred into 96-well plates 
with complete DMEM media (i.e., DMEM plus 10% fetal calf serum, 2 mM L-glutamine, 
100 μM/mL penicillin, 100 μg/mL streptomycin). The plates were maintained overnight at 
37 °C in a humidified atmosphere of 5% CO2. Further, worms were then incubated up to 72 
h with 0.10–100 μM of selected compounds and PZQ or negative control DMSO at 0.1%. 
The effect of the compounds on adult worm motility or phenotype was assessed either 
immediately 24, 48, or 72 h after compound addition using a newly developed HCS assay. 
Our method uses 100 time-lapse images captured every 250–300 ms with an automated 
bright-field microscope using a 2× objective lens (ImageXpress Micro XLS, Molecular 
Devices, CA). Subsequent quantitative image analysis used a custom-developed pipeline for 
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detecting changes in parasite motility and morphology using the open-source CellProfiler 
software v. 2.1.2.106 The pipeline along with its validation will be thoroughly described in a 
subsequent publication, and the pipeline itself is freely available (www.cellprofiler.org/
published_pipelines.shtml). Briefly, our strategy for motility measurement was based on 
sequential pairwise comparison of the 100 captured time-lapse images. The motility 
measurement called “AdjustedRandIndex” is calculated by comparing worm objects 
identified on images captured at times tn and tn−1 with CellProfiler’s CalculateImageOverlap 
module. This measure ranges from 0 to 1, with 1 meaning two objects are perfectly aligned 
(no movement). In addition to the “Overlap” mobility score, over 100 features related to 
size, shape, intensity, texture, and granularity are calculated for worm objects identified in 
the image analysis pipeline and saved in a database. These features are expected to describe 
different parasite phenotypes in response to drug exposure.
Cytotoxicity Assay—WSS-1 [WS-1](ATCCCRL-2029) epithelial cells derived from 
human kidney were grown in DMEM medium, supplemented with 4.5 g/L glucose, 50 
μg/mL gentamicin, and 10% fetal bovine serum, and seeded into 96-well microplates at 5 × 
104 cells/mL. Twenty hours later, cells were exposed to 0.2–400 μM of PZQ, OLT, and 
LabMol compounds and kept under a humidified atmosphere (37 °C, 5% CO2) for 48 h. To 
evaluate the cytotoxic effects of the compounds, the fluorescent viability dye resazurin was 
added to each well at a final concentration of 0.01 mg/mL 4 h before the end of the 
incubation. Resorufin fluorescence readings (λex = 560 nm, λem = 590 nm) were performed 
immediately and 4 h after resazurin addition in a FlexStation 3 Benchtop multi-mode 
microplate reader (Molecular Devices, Sunnyvale, CA). The percentage of viable cell was 
calculated using cells treated only with DMSO (0.2–0.8%) as controls.
Colloidal Aggregation Assay—Adult worms were coincubated with compounds (at 20 
and 100 μM) and detergent Triton X-100 (0.01%). The, motility measurements were 
performed after 48 h and 72 h, and their antischistosomal effect was compared with 
activities obtained without detergent.
Papain Inhibition Assay—Enzymatic assay was performed at 37 °C in 100 mM sodium 
acetate buffer, pH 3.5. Positive control E-64 and compounds were incubated at 20 and 100 
μM concentrations for 5 min with papain (5 μg/mL), and the reaction was initiated with the 
addition of 50 μM Z-FR-AMC fluorogenic peptide substrate.
Statistical Analysis—One-way ANOVA followed by Tukey’s multiple comparisons test 
was performed using GraphPad Prism v.5.00 (GraphPad Software, La Jolla California USA, 
www.graphpad.com). The EC50 and CC50 values were determined by four-parameter logist 
curve function using the same software. EC50 values obtained for adult worms were 
calculated using TIBCO Spotfire software (Boston, MA).
Ethics Statement—Animal’s maintenance and experiments were carried out in 
accordance with the Institutional Ethics Committee for Laboratory Animal Use at the 
Oswaldo Cruz Foundation (CEUA/FIOCRUZ, Brazil; license no. L-044/15).
Neves et al. Page 16
J Med Chem. Author manuscript; available in PMC 2018 March 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
AD applicability domain
CART classification and regression trees
CC50 half-maximal cytotoxic concentration
CDK chemistry development kit
EC50 half-maximal motility concentration
FN false negatives
FP false positives
GBM gradient boosting machine
GR glutathione reductase
GSH glutathione
GSSG glutathione disulflde
HCS high content screening
IC50 half-maximal inhibitory concentration
kNN k-nearest neighbors
MACCS Molecular ACCess System (MACCS) keys
MARS multivariate adaptive regression splines
MLP multilayer perceptron
NADPH nicotinamide adenine dinucleotide phosphate
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OECD Organization for Economic Cooperation and Development
OLT oltipraz
PCA principal component analysis
PLS-DA partial least-squares discriminant analysis
PPMs predicted probability maps
PZQ praziquantel
QSAR quantitative structure–activity relationships
RF random forest
S. mansoni Schistosoma mansoni
SAR structure–activity relationships
SE sensitivity
SMARTS SMILES arbitrary target specification
SmTGR S. mansoni TGR
SP specificity
SVM support vector machine
TGR thioredoxin glutathione reductase
TN true negatives
TP true positives
TR thioredoxin reductase
Trx thioredoxin
VS virtual screening
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Figure 1. 
Favorable fragments (green) for SmTGR inhibition predicted by the best individual QSAR 
model and their respective frequencies in inhibitors and noninhibitors sets.
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Figure 2. 
Unfavorable fragments (purple) for SmTGR inhibition predicted by the best individual 
QSAR model and their respective frequencies in inhibitors and noninhibitors sets.
Neves et al. Page 26
J Med Chem. Author manuscript; available in PMC 2018 March 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Predicted probability maps generated for oxadiazoles (A, B, and C) and their proposed 
reaction mechanism in the SmTGR active site (D).
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Figure 4. 
QSAR-based VS workflow used for identifying new compounds active against S. mansoni.
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Figure 5. 
Chemical structures of six priority hits selected for further follow up.
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Figure 6. 
Phenotypes of schistosomula exposed for 48 h to 0.625% DMSO (control, A), 20 μM of 4 
(B), and 10 μM of PZQ (C) and OLT (D). The outlines represent the position of each 
parasite over 5 time points (11 s interval).
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Figure 7. 
3D scatter plot of the top three image features correlated to antischistosomal activity of the 
investigated compounds on female S. mansoni worms after 48 h drug exposure. Each point 
in the graph represents a well/condition in the assay. Sample images are shown for selected 
wells to illustrate the different phenotypes captured by these three parameters (OA, object 
area; MS, mobility score; PI, pixel intensity of the worm object). The green outlines 
represent the position of each parasite over five time points (3 s interval) overlaid on the 
initial position (red outline).
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